Fig. 6

Cytotoxic activity of BCMA- and IL-13Rα2-specific TRuC-T cells. a BCMA-specific TRuCs were generated by fusing a BCMA-specific scFv to CD3ε, CD3γ or TCRβ subunits. Lysis of HeLa cells expressing BCMA (light blue) or, as control, expressing CD19 (grey) by the respective TRuC-T cells was measured at an effector-to-target cell ratio of 1:1. Graphs depict data from two independent experiments measured in triplicates. b Analysis of BCMA-specific ε-TRuC-T (light blue), γ-TRuC-T (green), β-TRuC-T (orange) or non-transduced control T cells (black) for anti-tumor activity in a RPMI-8226 NSG mouse model for multiple myeloma. Data from one experiment are shown. c An IL-13Rα2-specific ε-TRuC was generated by fusing a single-domain antibody (VHH) to CD3ε. IL-13Rα2-specific ε-TRuC-T (red) or non-tranduced (NT) T cells (black) were tested for in vitro lysis of U251 glioblastoma cells at various effector-to-target cell ratios. d Release of IL-2 and IFN-γ by IL-13Rα2-specific TRuC-T cells activated by U251 target cells. Figures c and d show data from four independent experiments measured in triplicates. e Activity of IL-13Rα2-specific ε-TRuC-T cells against subcutaneous U251 tumors in a NSG mouse model. Results from one experiment are shown. Data were log-transformed and analyzed using either two-way ANOVA followed by Dunnett’s multiple comparison test comparing all group means against the control group (vector control group for a or NT control group for b, c, and e) or two-tailed Student’s t-test. Overall P-value ≤ 0.0001 for a, b, c, and e. *** Adjusted-P ≤ 0.001; **** Adjusted-P ≤ 0.0001. Error bars in all graphs depict standard deviation